Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

73.70USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$73.70
Open
--
Day's High
--
Day's Low
--
Volume
1,029
Avg. Vol
10,408,473
52-wk High
$108.31
52-wk Low
$71.39

Select another date:

Wed, Nov 30 2016

Switching course, Gilead markets HIV drug for prevention

NEW YORK Gilead Sciences Inc has begun marketing its HIV treatment Truvada in a way thousands of consumers already use it – to prevent infection with the virus that causes AIDS.

Gilead, Merck to face off before jury over hepatitis C drug patents

Early next month, Gilead Sciences Inc will try to convince a federal jury in Delaware that a Merck & Co patent on hepatitis C drugs is invalid.

Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial

Gilead Sciences Inc has lost a bid to invalidate two Merck & Co patents on hepatitis C treatments, which Merck claims are infringed by Gilead's blockbuster Harvoni and Sovaldi.

BRIEF-Gilead announces top-line results from two phase 3 studies

* Gilead Sciences Inc - non-inferiority was not achieved for key secondary endpoint of response rate in total symptom score (TSS)

BRIEF-Gilead - data for combination of selonsertib, gs-9674 in rodent model of advanced fibrosis resulted in greater anti-fibrotic activity than either agent alone

* Gilead Sciences Inc - results demonstrate improvement in fibrosis stage among nash patients with moderate to severe fibrosis

UPDATE 1-Gilead's hepatitis B drug gets U.S. approval

Nov 10 Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved its drug to treat chronic hepatitis B infection in patients with scarred liver.

Gilead's hepatitis B drug wins U.S. approval

Nov 10 Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration approved its drug for patients with chronic hepatitis B virus infection.

J&J vaccine plus Gilead immune booster shows promise as HIV fighter

CHICAGO An experimental HIV vaccine from Johnson & Johnson combined with an immune system booster from Gilead Sciences Inc showed promise at keeping the virus at bay in monkeys even after treatments had stopped, marking yet another step toward the development of a so-called functional cure for HIV.

J&J vaccine plus Gilead immune booster shows promise as HIV fighter

CHICAGO, Nov 9 An experimental HIV vaccine from Johnson & Johnson combined with an immune system booster from Gilead Sciences Inc showed promise at keeping the virus at bay in monkeys even after treatments had stopped, marking yet another step toward the development of a so-called functional cure for HIV.

Gilead 3rd-quarter profit falls, HIV sales rise

Gilead Sciences Inc on Tuesday posted a 28 percent drop in quarterly net profit due to lower sales of its hepatitis C drugs Harvoni and Sovaldi, but its HIV drug sales beat Wall Street's expectations and the biotech company made no changes to its full-year outlook.

Select another date: